<circle stroke="#1e77f9" class="srdi68r9" cx="25" cy="25" r="20" fill="none" stroke-width="5">

Positive Outlook on Regeneron Amidst EYLEA Challenges: Strategic Focus on GLP-1 Therapies for Alzheimer’s

PremiumRatings

7d ago

Humana initiated, Paycom upgraded: Wall Street’s top analyst calls

PremiumThe Fly

11d ago

PremiumThe Fly

Regeneron, Sanofi announce CHMP opinion recommending Dupixent approval

11d ago

PremiumThe FlyRegeneron donates ebola treatment for use in countries at risk of outbreaks

14d ago

Regeneron announces updated analyses from Phase 2 COURAGE trial

The Fly

Regeneron announces updated analyses from Phase 2 COURAGE trial

16d ago

Regeneron announces primary endpoint met in Phase 3 OPTIMA trial

The Fly

Regeneron announces primary endpoint met in Phase 3 OPTIMA trial

16d ago

Buy Rating for Regeneron Amid Promising Allergy Treatment Trials and Strong Oncology Prospects

PremiumRatings

24d ago

Regeneron announces follow-up results on Phase 3 EMPOWER-Lung 3 trial

PremiumThe Fly

24d ago

Sandoz reaches agreement with Regeneron over patent litigation

PremiumThe Fly

24d ago

Regeneron announces results of Phase 3 trials on allergen-blocking antibodies

PremiumThe Fly

25d ago

PremiumThe FlySanofi’s ‘disappointing’ atopic dermatitis data sends Nektar higher

28d ago

AMGN

Video: Regeneron getting boost from competitor ‘disappointing’ data

The Fly

Video: Regeneron getting boost from competitor ‘disappointing’ data

28d ago

Sanofi’s ‘disappointing’ results to boost Regeneron shares, says Raymond James

The Fly

Sanofi’s ‘disappointing’ results to boost Regeneron shares, says Raymond James

29d ago

Early notable gainers among liquid option names on September 4th

AMGN

PremiumThe Fly

29d ago

ETR

HPE

PremiumThe Fly

Regeneron assumed with Outperform from Market Perform at Raymond James

1M ago

Regeneron’s Promising Factor XI Programs: A Potential Game-Changer in the Anticoagulation Market

PremiumRatings

1M ago

Regeneron price target raised to $781 from $753 at Bernstein

PremiumThe Fly

1M ago

PremiumThe FlyRegeneron announces Phase 3 NIMBLE trial met primary, key secondary endpoints

1M ago

Regeneron’s Promising Pipeline: Buy Rating Backed by EYLEA HD Progress and Anticipated Approvals

Ratings

Regeneron’s Promising Pipeline: Buy Rating Backed by EYLEA HD Progress and Anticipated Approvals

1M ago

Regeneron says FDA delayed review of two Eylea HD submissions

The Fly

Regeneron says FDA delayed review of two Eylea HD submissions

1M ago